Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sunami, Yoshitaka ^a   Araki, Marito ^a   Hironaka, Yumi ^a   Morishita, Soji ^a   Kobayashi, Masaki ^a,b   Liew, Ei Leen ^a,c   Edahiro, Yoko ^a   Tsutsui, Miyuki ^a   Ohsaka, Akimichi ^a   Komatsu, Norio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BML 266; ENZYME INHIBITOR; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; SHORT HAIRPIN RNA; SIRTUIN 1; SIRTUIN 2; TENOVIN 6; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN DEGRADATION;

APOPTOSIS; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS STRUCTURES; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; GRANULOCYTES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MODELS, BIOLOGICAL; NAD; ONCOGENE PROTEINS, FUSION; PROTEIN STABILITY; SIRTUIN 1; SIRTUIN 2;

EID: 84874542679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057633     Document Type: Article

References (54)

1. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, et al. (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113: 1875-1891.
2. Grimwade D, Lo Coco F, (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16: 1959-1973.
3. de The H, Chen Z, (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Reviews Cancer 10: 775-783.
4. Dellaire G, Bazett-Jones DP, (2004) PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963-977.
5. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, et al. (1996) Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 56: 2945-2948.
6. Isakson P, Bjoras M, Boe SO, Simonsen A, (2010) Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 116: 2324-2331.
7. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, et al. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330.
8. Amin HM, Saeed S, Alkan S, (2001) Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 115: 287-297.
9. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ueda R, et al. (2001) In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn J Cancer Res 92: 529-536.
10. Witt O, Deubzer HE, Milde T, Oehme I, (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
11. Yoo CB, Jones PA, (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
12. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
13. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP, (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625.
14. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, et al. (2002) Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 100: 2586-2596.
15. Minucci S, Nervi C, Lo Coco F, Pelicci PG, (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20: 3110-3115.
16. Nakagawa T, Guarente L, (2011) Sirtuins at a glance. Journal of Cell Science 124: 833-838.
17. Houtkooper RH, Pirinen E, Auwerx J, (2012) Sirtuins as regulators of metabolism and healthspan. Nature Reviews Molecular Cell Biology 13: 225-238.
18. Inoue T, Hiratsuka M, Osaki M, Oshimura M, (2007) The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6: 1011-1018.
19. Saunders LR, Verdin E, (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504.
20. Bosch-Presegue L, Vaquero A, (2011) The dual role of sirtuins in cancer. Genes Cancer 2: 648-662.
21. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C, (2011) Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol 2011: 368276.
22. Liu T, Liu PY, Marshall GM, (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69: 1702-1705.
23. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, et al. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3: e2020.
24. Wang RH, Sengupta K, Li CL, Kim HS, Cao L, et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323.
25. Li YZ, Matsumori H, Nakayama Y, Osaki M, Kojima H, et al. (2011) SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes to Cells 16: 34-45.
26. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, et al. (2003) Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochemical and Biophysical Research Communications 309: 558-566.
27. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, et al. (2011) SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity. Cancer Cell 20: 487-499.
28. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, et al. (2012) The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell 151: 1185-1199.
29. Van Meter M, Mao ZY, Gorbunova V, Seluanov A, (2011) SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 10: 3153-3158.
30. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, et al. (2009) NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nature Medicine 15: 151-158.
31. Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, et al. (2012) The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica-the Hematology Journal 97: 551-559.
32. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, et al. (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454-463.
33. Li L, Wang L, Wang Z, Ho Y, McDonald T, et al. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281.
34. Yuan H, Wang Z, Li L, Zhang H, Modi H, et al. (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119: 1904-1914.
35. Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, et al. (2013) SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 32: 589-598.
36. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, et al. (1997) Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia. Leukemia 11: 1950-1956.
37. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, et al. (1993) PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867.
38. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, et al. (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333-343.
39. Kiviranta PH, Leppanen J, Kyrylenko S, Salo HS, Lahtela-Kakkonen M, et al. (2006) N,N′-Bisbenzylidenebenzene-1,4-diamines and N,N′-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. J Med Chem 49: 7907-7911.
40. Ablain J, de The H, (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117: 5795-5802.
41. Schenk T, Chen WC, Gollner S, Howell L, Jin L, et al. (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine 18: 605-611.
42. Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, et al. (2004) Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood 104: 1314-1323.
43. Obsilova V, Silhan J, Boura E, Teisinger J, Obsil T, (2008) 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 57Suppl 3: S11-21.
44. Andersen JL, Thompson JW, Lindblom KR, Johnson ES, Yang CS, et al. (2011) A biotin switch-based proteomics approach identifies 14-3-3zeta as a target of Sirt1 in the metabolic regulation of caspase-2. Mol Cell 43: 834-842.
45. Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M, et al. (2005) Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes to Cells 10: 321-332.
46. Myatt SS, Brosens JJ, Lam EWF, (2011) Sense and Sensitivity: FOXO and ROS in Cancer Development and Treatment. Antioxidants & Redox Signaling 14: 675-687.
47. Zhao Y, Yang J, Liao WJ, Liu XY, Zhang H, et al. (2010) Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nature Cell Biology 12: 665-U688.
48. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li HZ, et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377.
49. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.
50. Newburger PE, Chovaniec ME, Greenberger JS, Cohen HJ, (1979) Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 82: 315-322.
51. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
52. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, et al. (2004) Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng 87: 537-545.
53. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E, (2003) The human Sir2 ortholog, SIRT2, is an NAD(+)-dependent tubulin deacetylase. Mol Cell 11: 437-444.
54. Collins SJ, (1987) The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70: 1233-1244.